Genentech's New Deal Maker
This article was originally published in Start Up
In a wide-ranging interview just four days after joining Genentech, the biotech's new head of business development outlines his team's mission, which emphasizes early-stage novel assets arising from academia and biotech.
You may also be interested in...
The recent appointment of James Sabry, MD, PhD, as Genentech's new head of business development is Roche's latest attempt to retain the spirit of the once-independent biotech icon.
As Big Pharmas seek to hedge their development risk and look for more externally sourced programs, partnerships with academic institutions are one of the many ingredients in the R&D secret sauce. Such deals aren't the academic-industry tie-ups of yore-where Big Pharma sought small money partnerships without giving a lot back to their academic partners. Business development execs view them as yet another way to access critically important innovation.
What does Roche's privatization of Genentech mean for the companies' business development organizations and current and future partners? We recently sat down with the company's two business development chiefs to find out.